The new pattern and new drivers of development are accelerating

Shanghai is an important birthplace of national industry in modern China, the birthplace and gathering place of national brands, and the inheritance and development flow continuously. Shanghai’s “13th Five-Year Plan” proposes to accelerate the development of strategic emerging industries, including next-generation information technology, intelligent manufacturing equipment, biomedicine and high-end medical devices, new energy and intelligent connected vehicles, aerospace, etc. The “14th Five-Year Plan” proposes to build a “3+6” new industrial system, namely, the three leading industries of integrated circuits, biomedicine and artificial intelligence, and the six key industries of electronic information, life and health, automobiles, high-end equipment, advanced materials and fashion consumer goods. Since 2021, Shanghai has laid out four new tracks: digital economy, green and low-carbon, meta-universe, and intelligent terminal, and planned five future industries such as future health, future intelligence, future energy, future space, and future materials, and continuously consolidated the modern industrial system.

IC393MDL940

As one of the three leading industries in Shanghai, the scale of Shanghai’s biomedical industry will reach 853.6 billion yuan in 2022 and is expected to exceed one trillion yuan by 2025. Since 2019, a total of 19 first-class innovative drugs have been approved in Shanghai, accounting for about 1/4 of the country, and 26 third-class innovative medical devices have been approved, accounting for about 1/6 of the country.

Recently, Qin Nan, chairman of Rui Yi, took a number of tumor early detection products to participate in the 75th American Clinical Chemistry Annual Meeting and Clinical Experimental Medicine Expo. “At present, the company’s product pipeline widely covers a number of high-incidence cancers such as colorectal cancer, bladder cancer, cervical cancer, and so on. This exhibition, competing with products from different countries and exchanging cutting-edge technologies with experts from all sides, will help us more accurately deepen the field of early detection of tumors, and accelerate the promotion of more high-incidence cancer early screening technologies and products to the world.” Qin Nan said.

In order to make products more beneficial to the people and make enterprises more innovative, on July 31, Shanghai multi-departments jointly issued the “Several Measures for Shanghai to further improve the multi-payment Mechanism to Support the development of innovative pharmaceutical devices”. “This reflects Shanghai’s emphasis on and support for the sustainable and high-quality development of the innovative biomedical industry, and gives the innovative pharmaceutical industry a clear expectation of positive benefits.” Huang Yifeng, vice president of Beigene, said that a series of “combined fists” will “escort” the high-quality development of innovative pharmaceutical devices, and will make innovative pharmaceutical companies more confident to invest in research and development.